MarketResearchReports.com: Bone Metastasis - Pipeline Review, H2 2013, New Report Launched

Bone Metastasis Pipeline Review, H2 2013 , provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bone Metastasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Metastasis. Bone Metastasis Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Bone Metastasis.
• A review of the Bone Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Bone Metastasis pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Bone Metastasis.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

In addition to covering the Bone Metastasis Overview, An Overview of Pipeline Products for Bone Metastasis, Companies Involved in Bone Metastasis Therapeutics Development, Bone Metastasis Therapeutics - Drug Profile Updates, Bone Metastasis Therapeutics - Discontinued Products, Bone Metastasis Therapeutics - Dormant Products.  The report covers 18 companies Johnson & Johnson, Celsion Corporation, Amgen Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Bayer AG, Medivir AB, Osteologix, Inc., Transgene SA, Green Cross Corporation, Merrion Pharmaceuticals Plc, Digna Biotech, S.L., Debiopharm Group, Amura Holdings Ltd., Alethia Biotherapeutics Inc., Deciphera Pharmaceuticals, LLC, Targa Therapeutics Corp. and America Stem Cell, Inc.

Find all Diseases Market Research Reports  under a single page at: Diseases Market Research Reports